Regeneron and Bayer have faced a defeat in the UK in their global dispute against several generic companies over their ophthalmic drug Eylea. The London High Court found the patents-in-suit not
Once again, Regeneron and Bayer have successfully defended their ophthalmic drug Eylea on the German market and beyond. Munich Regional Court yesterday granted a preliminary injunction against Stada
total 1 pages, 2 items